Pharmacokinetics, pharmacodynamics and efficacy of multiple escalating SC doses of ligelizumab versus omalizumab and placebo in patients with allergic asthma

Trial Profile

Pharmacokinetics, pharmacodynamics and efficacy of multiple escalating SC doses of ligelizumab versus omalizumab and placebo in patients with allergic asthma

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Ligelizumab (Primary) ; Omalizumab
  • Indications Allergic asthma
  • Focus Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 30 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top